Millions of People Will Be Blindsided in 2023. Will You Be One of Them?

On December 13, Louis Navellier, Eric Fry & Luke Lango will reveal the major events that could rock the markets in 2023. Will your money be safe?

Tue, December 13 at 4:00PM ET

Why Is Jaguar Health (JAGX) Stock Up Today?

Jaguar Health (NASDAQ:JAGX) is a big mover in the market right now. Today’s upward move of 25% is a nice reversal of momentum, given the fact that JAGX stock has given up approximately 90% of its value over the past year.

The Jaguar Health logo on a tablet in front of a doctor.
Source: Spyro the Dragon/

As a commercial-stage pharmaceuticals company, Jaguar Health has a number of products that have garnered attention of late. Among the company’s key drugs is Mytesi, which focuses on the noninfectious diarrhea market “in adults with HIV/AIDS on antiretroviral therapy.”

That said, Jaguar Health has a rather impressive pipeline of drugs investors are watching as well. However, with little in the way of meaningful announcements on many of these drugs, investors appear to have lost interest in Jaguar Health relative to other options in the pharma space.

Today, though, investors have something to hang their hats on. Let’s dive into the recent update with JAGX and why this stock is taking off.

JAGX Stock Surges on Distribution Agreement for Key Drug

Today, Jaguar Health announced that it has entered into a distribution and license agreement with Quadri Pharmaceuticals. This agreement will cover the “promotional, commercialization, and distribution rights” for Jaguar Health’s crofelemer drug, Mytesi.

This drug currently has approval in the U.S. for HIV-related diarrhea. Approval for cancer-related diarrhea is currently waiting on the results of a key Phase 3 trial. Accordingly, there’s a lot to like about with this drug in the United States.

That said, this agreement focuses on other key global markets as well. Some of the targeted markets include Bahrain, Saudi Arabia, the United Arab Emirates (UAE) and Oman, among others. Currently, investors appear to like the global nature of the deal and growth the partnership could provide.

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that’s writers disclose this fact and warn readers of the risks.

Read More:Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, Chris MacDonald did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Chris MacDonald’s love for investing led him to pursue an MBA in Finance and take on a number of management roles in corporate finance and venture capital over the past 15 years. His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Article printed from InvestorPlace Media,

©2022 InvestorPlace Media, LLC